61
Simon Bailey, Christopher Gordon Barber, Paul Alan Glossop, Donald Stuart Middleton: Nicotinamide derivatives useful as PDE4 inhibitors. Pfizer, Charles W Ashbrook, Rosanne Goodman, November 28, 2006: US07141586

This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein each substituent is defined herein.


62
J Craig Franklin, Eric Mayhew, Walter Perkins, Andrew Janoff: Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, August 3, 1999: US05932242

Pharmaceutical compositions are provided herein that contain, in addition to a pharmaceutically acceptable carrier, a lamellar lipid. The lipid is composed of an ether lipid and a lipid having a molecular shape that is complementary to the molecular shape of the glycerolipid. These compositions can ...


63
J Craig Franklin, Eric Mayhew, Walter Perkins, Andrew Janoff: Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof. The Liposome Company, Rosanne Goodman, January 25, 2000: US06017557

Lipid-based carriers are provided herein that have a lamellar lipid component composed of an etherlipid and a complementarily shaped lipid. This novel combination of lipids allows for the incorporation of etherlipids in the carriers at higher concentrations than would otherwise be possible. Pharmace ...


64
James Bernard Kramer, Howard Daniel Hollis Showalter: Pyridotriazines and pyridopyridazines. Rosanne Goodman, Warner Lambert Company, May 23, 2002: US20020061865-A1

This invention relates to bicyclic heterocycles that inhibit cyclin-dependent kinase or tyrosine kinase enzymes, or both, and as such are useful to treat cell proliferative disorders such as angiogenesis, atherosclerosis, restenosis, and cancer as well as immunological disorders such as asthma, rheu ...


65
Hubert Barth, Klaus Steiner, Simon Schneider, Dietmar Huls, Andreas Muhlenfeld, Manfred Westermayer: Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride. Rosanne Goodman, Warner Lambert Company, February 19, 2004: US20040034022-A1

There are described polymorphic forms/hydrates of N-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, processes for their preparation, as well as the use of the same for the preparation of medicaments with irreversible tyrosine kinase inhibit ...


66
Mark Barvian, Richard John Booth, John Ouin, Joseph Thomas Repine, Derek J Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou: 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones. Rosanne Goodman, Warner Lambert Company, August 7, 2003: US20030149001-A1

The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4). 1


67
Richard John Booth, Ellen Myra Dobrusin, Vara Prasad Venkata Nagendra Josyula, Dennis Joseph McNamara, Peter Laurence Toogood: Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. Rosanne Goodman, Warner Lambert Company, April 17, 2003: US20030073668-A1

Disclosed are compounds of the formula (I) wherein: R2, R7, RI3, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH2)nR12; R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9; R6 is halogen, cyan ...


68
Hubert Barth, Klaus Steiner, Simon Schneider: Method for the simplified production of (3-chloro-4-flourophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine. Rosanne Goodman, Warner Lambert Company, March 13, 2003: US20030050313-A1

The invention concerns a one-pot reaction for the preparation of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitroquinazolin-4-yl]-amine (I) 1 or of (3-chloro-4-fluorophenyl)-[7-(3-morpholino-4-yl-propoxy)-6-aminoquinazolin-4-yl]-amine (VII) 2


69
Alexander James Bridges: Irreversible inhibitors of tyrosine kinases. Rosanne Goodman, Warner Lambert Company, May 8, 2003: US20030087881-A1

The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyros ...


70
William Alexander Denny, Gordon William Rewcastle, Ellen Dobrusin, James Bernard Kramer, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Peter Laurence Toogood: Pteridinones as kinase inhibitors. Rosanne Goodman, Warner Lambert Company, July 10, 2003: US20030130286-A1

Disclosed are compounds of Formulae (Ia), (Ib), (Ic), (Id) wherein: W is NH, S, SO, or SO2; R2 is (un)substituted aryl, (un)substituted heteroaryl, or (un)substituted carbocycle or heterocycle; Q is hydrogen or lower alkyl; R4 and R6 are the same or different and represent hydrogen, halogen, lower a ...